PHASE 1 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, INTRA-SUBJECT STUDY TO ASSESS LOCAL TOLERABILITY OF CRISABOROLE 2% OINTMENT AND VEHICLE IN HEALTHY PARTICIPANTS USING SUBJECT-REPORTED ASSESSMENTS AND OBJECTIVE MEASUREMENTS
Latest Information Update: 25 Jun 2019
At a glance
- Drugs Crisaborole (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Pfizer
- 22 May 2019 Status changed from recruiting to completed.
- 18 Feb 2019 Planned End Date changed from 2 Apr 2019 to 16 Apr 2019.
- 18 Feb 2019 Planned primary completion date changed from 2 Apr 2019 to 16 Apr 2019.